Green Darren, Ritchie James P, Chrysochou Constantina, Kalra Philip A
Institute of Cardiovascular Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK.
Vascular Research Group, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre, Salford, UK.
Nephrology (Carlton). 2018 May;23(5):411-417. doi: 10.1111/nep.13038.
The aim of the study is to determine whether the apparent benefit of revascularization of renal artery stenosis for 'flash' pulmonary oedema extends to heart failure patients without a history of prior acute pulmonary oedema.
A prospective study of patients with renal artery stenosis and heart failure at a single centre between 1 January 1995 and 31 December 2010. Patients were divided into those with and without previous acute pulmonary oedema/decompensation. Survival analysis compared revascularization versus medical therapy in each group using Cox regression adjusted for age, estimated glomerular filtration rate, blood pressure and co-morbidities.
There were 152 patients: 59% male, 36% diabetic, age 70 ± 9 years, estimated glomerular filtration rate 29 ± 17 mL/min per 1.73 m ; 52 had experienced previous acute pulmonary oedema (34%), whereas 100 had no previous acute pulmonary oedema (66%). The revascularization rate was 31% in both groups. For heart failure without previous acute pulmonary oedema, the hazard ratio for death after revascularization compared with medical therapy was 0.76 (0.58-0.99, P = 0.04). In heart failure with previous acute pulmonary enema, the hazard ratio was 0.73 (0.44-1.21, P = 0.22). For those without previous acute pulmonary oedema, the hazard ratio for heart failure hospitalization after revascularization compared with medical therapy was 1.00 (0.17-6.05, P = 1.00). In those with previous acute pulmonary oedema, it was 0.51 (0.08-3.30, P = 0.48).
The benefit of revascularization in heart failure may extend beyond the current indication of acute pulmonary oedema. However, findings derive from an observational study.
本研究旨在确定肾动脉狭窄血运重建对“急性”肺水肿的明显益处是否也适用于无既往急性肺水肿病史的心力衰竭患者。
对1995年1月1日至2010年12月31日期间在单一中心的肾动脉狭窄和心力衰竭患者进行前瞻性研究。患者被分为有和无既往急性肺水肿/失代偿史两组。生存分析采用Cox回归,对每组血运重建与药物治疗进行比较,并对年龄、估计肾小球滤过率、血压和合并症进行校正。
共有152例患者,男性占59%,糖尿病患者占36%,年龄70±9岁,估计肾小球滤过率为每1.73平方米29±17毫升/分钟;52例有既往急性肺水肿病史(34%),而100例无既往急性肺水肿病史(66%)。两组的血运重建率均为31%。对于无既往急性肺水肿的心力衰竭患者,血运重建后与药物治疗相比的死亡风险比为0.76(0.58 - 0.99,P = 0.04)。在有既往急性肺水肿的心力衰竭患者中,风险比为0.73(0.44 - 1.21,P = 0.22)。对于无既往急性肺水肿的患者,血运重建后与药物治疗相比的心力衰竭住院风险比为1.00(0.17 - 6.05,P = 1.00)。在有既往急性肺水肿的患者中,该风险比为0.51(0.08 - 3.30,P = 0.48)。
心力衰竭患者血运重建的益处可能超出目前急性肺水肿的适应证范围。然而,这些发现来自一项观察性研究。